Lead Product(s) : Amifampridine
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Jacobus Pharmaceutical Company, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Details : 3,4-Diaminopyridine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscle Weakness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2014
Lead Product(s) : Amifampridine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Jacobus Pharmaceutical Company, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Details : 3,4-DAP is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lambert-Eaton Myasthenic Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2012
Lead Product(s) : Amifampridine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
